Developing Vaccines against Flavivirus Diseases: Past Success, Present Hopes and Future Challenges
- Gregory Bock Organizer,
- Jamie Goode
Published Online: 7 OCT 2008
DOI: 10.1002/0470058005.ch14
Copyright © Novartis Foundation 2006
Book Title
New Treatment Strategies for Dengue and Other Flaviviral Diseases: Novartis Foundation Symposium 277
Additional Information
How to Cite
Stephenson, J. R. (2008) Developing Vaccines against Flavivirus Diseases: Past Success, Present Hopes and Future Challenges, in New Treatment Strategies for Dengue and Other Flaviviral Diseases: Novartis Foundation Symposium 277 (eds G. Bock and J. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470058005.ch14
Publication History
- Published Online: 7 OCT 2008
- Published Print: 25 AUG 2006
ISBN Information
Print ISBN: 9780470016435
Online ISBN: 9780470058008
- Summary
- Chapter
Keywords:
- dengue vaccine and vaccine development;
- vaccine delivery barriers;
- conventional immunization strategies;
- immune stimulators and vaccine efficiency;
- non-structural protein based vaccine
Summary
Vaccination still remains the most cost-effective way of protecting large populations against infectious disease. Safe and effective vaccines are available against most pathogenic flaviviruses and in recent years substantial progress has been made in developing vaccines against dengue. Dengue vaccines based on conventional and recombinant DNA technologies are being assessed and initial results are encouraging. Many other experimental vaccines have been developed, but despite the intensity of effort, concerns about the safety of new vaccines appear to be hindering their development. With the global threat from dengue increasing, might it now be the time to consider a less riskaverse approach?